Published in Drugs on July 01, 1996
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 1.12
Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol (1999) 1.10
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. J Mol Biol (2008) 1.09
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1997) 1.00
Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother (2004) 0.95
Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol (2004) 0.92
Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention. Antimicrob Agents Chemother (2012) 0.88
Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol (2002) 0.88
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol (2001) 0.86
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol (2000) 0.82
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol (1999) 0.77
CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism. Drug Metab Dispos (2013) 0.76
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Antimicrob Agents Chemother (1998) 0.75
Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats. Drug Des Devel Ther (2016) 0.75
Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC. J Clin Immunol (1998) 0.75
Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs (1992) 2.53
Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs (1992) 1.93
Orientation-dependent recombination hotspot activity in bacteriophage lambda. J Mol Biol (1979) 1.89
Meloxicam. Drugs (1996) 1.75
Ropivacaine: an update of its use in regional anaesthesia. Drugs (2000) 1.60
Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 1.59
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs (1994) 1.52
Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs (1997) 1.46
An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol (1998) 1.45
The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem (1998) 1.42
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs (1993) 1.41
Propofol. An update of its use in anaesthesia and conscious sedation. Drugs (1995) 1.39
Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs (1994) 1.37
Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs (1996) 1.34
Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs (1992) 1.34
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs (1991) 1.34
Etanercept: a review of its use in rheumatoid arthritis. Drugs (1999) 1.32
Amprenavir. Drugs (1998) 1.29
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs (1993) 1.25
Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs (1999) 1.23
Chi. Cold Spring Harb Symp Quant Biol (1979) 1.20
Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs (1995) 1.14
Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs (1997) 1.10
Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs (1990) 1.09
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci U S A (1995) 1.09
Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs (1999) 1.08
Esomeprazole. Drugs (2000) 1.08
Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs (1992) 1.07
Break-join recombination in phage lambda. Genetics (1990) 1.06
Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs (1993) 1.06
Ritonavir. Drugs (1996) 1.05
Lopinavir. Drugs (2000) 1.05
Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review. Pharmacoeconomics (1999) 1.04
Members of the 70 kDa heat shock protein family specifically recognize sulfoglycolipids: role in gamete recognition and mycoplasma-related infertility. J Cell Physiol (1995) 1.04
Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs (1994) 1.03
Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs (1994) 1.02
Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs (1998) 1.02
Montelukast. Drugs (1998) 1.01
Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs (1998) 1.01
Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Drugs (1996) 1.01
Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs (1992) 0.99
Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs (1994) 0.99
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs (1999) 0.98
Rabeprazole. Drugs (1998) 0.96
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs (1992) 0.96
Abacavir. Drugs (1998) 0.95
Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs (1996) 0.94
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs (1997) 0.94
Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs (1995) 0.94
Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs (1990) 0.94
Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs (1996) 0.92
Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs (1995) 0.92
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs (1991) 0.92
Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging (1994) 0.91
Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs (1993) 0.91
Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs Aging (1994) 0.89
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs (1992) 0.89
Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs (1999) 0.88
Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs (1999) 0.88
Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging (1997) 0.87
Theophylline. A review of its potential steroid sparing effects in asthma. Drugs (1998) 0.87
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs (1997) 0.86
Nateglinide. Drugs (2000) 0.86
The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol (2000) 0.85
Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs (1994) 0.85
Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs (1992) 0.85
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs (1996) 0.84
Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs (1993) 0.83
Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs (1997) 0.83
Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs (1992) 0.83
Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs (1992) 0.83
Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics (2000) 0.83
Repaglinide. Drugs Aging (1998) 0.83
Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging (1996) 0.83
Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs (1994) 0.82
Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs (1991) 0.82
Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias. Drugs (1992) 0.82
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs (1995) 0.82
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging (1995) 0.81
Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs (1998) 0.80
Samarium 153Sm lexidronam. Drugs Aging (1997) 0.80
Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs (1997) 0.80
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics (1993) 0.80
Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs Aging (1994) 0.79
Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs (1994) 0.79
Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Pharmacoeconomics (1994) 0.79
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs (1995) 0.79
Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. Pharmacoeconomics (1994) 0.78
Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drugs Aging (1994) 0.78
Rizatriptan: a review of its efficacy in the management of migraine. Drugs (1999) 0.78
Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging (1998) 0.78
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs (1995) 0.77
Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J Mol Med (Berl) (1997) 0.77
Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging (1993) 0.77
Ganirelix. Drugs (2000) 0.77
Aldesleukin (recombinant interleukin-2). BioDrugs (1997) 0.77
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs (1991) 0.76
Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs (1996) 0.76
Cyclosporin: a review of its pharmacology and clinical potential in the treatment of systemic lupus erythematosus. BioDrugs (1997) 0.76